Apart from bronchodilation, ADRB2 genetic variations may also alter receptor desensitization and agonist-promoted downregulation, adding further complexity to the pharmacogenetic landscape of β2-agonists in COPD treatment. The gene discussed is ADRB2; the disease is chronic obstructive pulmonary disease.